Biotech
Pfizer Just Paid $330 Million to Skip Cell Therapy's Hardest Step
Pfizer is paying $330M up front, up to $2.6B total, for three in vivo CAR-T programs from China's Starna, a bet it can make cell therapy injectable.
Topic
The latest CAR-T news and analysis from Tech Arcade.
Pfizer is paying $330M up front, up to $2.6B total, for three in vivo CAR-T programs from China's Starna, a bet it can make cell therapy injectable.
BrainChild Bio raised $116M to run the pivotal trial for BCB-276, a CAR-T that pushed DIPG survival from ~11 to 19.8 months in a cancer that has beaten every drug for 50 years.